Viking Therapeutics (VKTX) is identified by Oppenheimer among five potential biotech M&A candidates ahead of J.P. Morgan Healthcare Conference. Read more here.

I suspected most financial assets were in 401(k) plans and most 401(k) holdings were directed by target-date funds, but the ...

As of December 30, 2024, the Company had utilized substantially all of the total authorized value for the 2024 Share Repurchase Plan. Specifically, the Company had in aggregate purchased 15,110,617 ...

Despite recent setbacks, HCA Healthcare's underlying business remains strong, with EPS expected to be at least $21.60. Read ...